Barclays Starts Chiasma (CHMA) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- Copart nears $2B all-cash deal to acquire ACV Auctions - Bloomberg
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
William Blair Starts Chiasma (CHMA) at Outperform
August 10, 2015 7:28 AM EDTWilliam Blair initiated coverage on Chiasma (NASDAQ: CHMA) with an Outperform rating and a price target of $40.00.
For an analyst ratings summary and ratings history on Chiasma click here. For more ratings news on Chiasma click here.
Shares of Chiasma closed at $23.83 yesterday.
... MoreCowen Starts Chiasma (CHMA) at Outperform
August 10, 2015 6:25 AM EDTCowen initiates coverage on Chiasma (NASDAQ: CHMA) with a Outperform rating and a price target of $43.00.
Analyst Ritu Baral commented, "We think Chiasma's TPE-Octreotide will become a key acromegaly treatment in the US/EU. We expect FDA to approve TPE-Octreotide in mid 2016,... More
